Chondrocytes

What it actually is

Chondrocytes are the sole resident cell of hyaline cartilage. They sit in lacunae inside a dense matrix they build themselves — type II collagen and aggrecan — and they divide almost never in adult tissue. That last fact is why cartilage does not heal on its own, and it is the entire clinical rationale for taking chondrocytes out, multiplying them in a laboratory, and putting them back.

Where it comes from

Autologous. A surgeon takes a small biopsy of healthy cartilage from a non-load-bearing part of the patient's own knee during an arthroscopy. There is no donor, no immune matching and no rejection risk — but there are two operations, and the cells are unique to one person, which is why the economics are unlike any allogeneic product.

How it is made — and what can go wrong

The biopsy is enzymatically digested, chondrocytes are released and expanded in culture over several weeks, then formulated. Spherox forms them into free-floating spheroids that self-assemble matrix before implantation. The critical manufacturing risk is dedifferentiation: chondrocytes grown flat on plastic progressively stop behaving like cartilage cells and start behaving like fibroblasts, producing type I instead of type II collagen. Controlling passage number is therefore a release-critical parameter, not a detail.

Regulatory status

Spherox received EU marketing authorisation in July 2017 for symptomatic articular cartilage defects of the femoral condyle and patella up to 10 cm² in adults. ChondroCelect was authorised earlier and later withdrawn commercially. This is a genuine, narrow, surgeon-delivered indication — not a general joint treatment.

What the evidence shows

Comparative trials have measured autologous chondrocyte implantation against microfracture using patient-reported knee scores. The indication is focal cartilage defects in an otherwise sound joint. Generalised osteoarthritis is a different disease with a different failure mode, and approval for the former is not evidence for the latter.

Limits worth knowing

Requires two surgeries and a long rehabilitation. Restricted by defect size, defect location, patient age and joint alignment. Does not apply to diffuse arthritic joints. If a clinic offers 'chondrocyte therapy' as an injection for general arthritis, that is not the authorised product or the authorised use.

What this could actually be used for

Chondrocytes are the only cell that builds and maintains hyaline cartilage. They sit isolated in a matrix they secrete themselves, with no blood supply reaching them, and in adult tissue they barely divide. That isolation is precisely why cartilage does not repair itself.

The clinical logic is narrow, mechanical and unusually honest about being so: take the cell that makes cartilage, grow more of it outside the body, put it back where cartilage is missing. No immune modulation, no signalling story, no systemic effect.

Focal cartilage defects 12 studies registered

A defined hole in otherwise healthy cartilage, usually from trauma in a younger knee. Cells are harvested at one operation, expanded for weeks, and implanted at a second. What has to happen is that they lay down matrix which integrates with the cartilage at the rim — which is why the condition of that rim decides the outcome more than the cells do. This is the one indication where the approach reached authorised medicines in Europe. All cell therapy research registered for this condition →

Delaying joint replacement

The stated aim is not reversing arthritis but postponing a prosthesis in a patient too young to spend one. A knee replacement has a service life; buying a decade before that clock starts is a real clinical goal even when nothing is cured.

Ankle and hip surfaces

The same operation applied to smaller, harder-to-reach joint surfaces, where the hardware alternative is worse and the defects tend to be focal rather than diffuse.

Nose, ear and airway cartilage

Outside joints entirely. The problem reconstructive surgery faces here is a shortage of shapeable cartilage, so a laboratory-grown sheet answers a supply problem rather than a biological one.

Intervertebral disc

The disc nucleus is cartilage-like tissue that degenerates with age. Attempts to repopulate it meet a harsher version of the knee problem: the disc has almost no blood supply at all, so anything implanted has to survive the conditions that killed the original cells.

Where it stops. Widespread arthritic wear is a different problem from a focal defect. Filling one hole in a joint whose entire surface is failing does not address the joint, and that distinction decides whether the approach makes any sense for a given patient.

What the registry actually shows for this cell type

Our own count of every study registered on ClinicalTrials.gov under this cell type, retrieved 2026-09-04. A registration is a declaration of intent, not a result — which is why the status column matters more than the total does.

Reading it: 9 studies stopped before finishing — terminated, withdrawn or suspended, 10% of the total; 33 studies carry no assigned trial phase, meaning they sit outside the phased development path that leads to an approved medicine; 36 studies reached Phase 2 or later, against 21 studies still at Phase 1 or earlier; 16 records have not had a status update from the sponsor and may be dormant.

The directions above describe where the biology points and where research has been registered. They are not claims that any of it works, not evidence of benefit, and not a treatment recommendation. Counts are our own extraction from the ClinicalTrials.gov API, retrieved 2026-09-04; the queries behind them are published with the dataset so that anyone can repeat the count.

What to ask before agreeing to anything

1. Is the product an authorised medicine, and is the proposed use inside its authorised indication?
2. Which surgeon performs the implantation, and where is the rehabilitation protocol documented?
3. What is the defect size, grade and location on imaging — and does it fall inside the label?
4. At what passage number are the cells released, and how is dedifferentiation controlled?

Sources behind the numbers on this page

• PubMed — Chondrocytes
• ClinicalTrials.gov — registered studies
• EMA — advanced therapy medicinal products
• FDA — cellular and gene therapy products

Study counts above are our own extraction from ClinicalTrials.gov; the links let you reproduce them. Not medical advice, and not an assessment of whether any treatment is appropriate for you.